Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Poor response to clopidogrel: current and future options for its management


Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary syndromes and/or undergoing percutaneous coronary interventions (PCI). Clopidogrel, a thienopyridine antiplatelet agent, has been used to prevent vascular complication in atherothrombotic patients, to prevent stent trombosis in patients undergoing PCI, and in long term prevention of cardiovascular and cerebrovascular events. More than 40 million patients in the world receive clopidogrel but unfortunately about 20% of these are either non or poor responders. Several methods have been used to assess clopidogrel-induced antiplatelet effects. However, none of these tests have been fully standardized or fully agreed upon to measure clopidogrel responsiveness. Nevertheless, many studies using different techniques, platelet agonists and definitions, showed that patients with a poor response to clopidogrel have an increased risk of death, reinfarction and stent thrombosis. The mechanisms leading to poor responsiveness are not fully clarified and are likely multifactorial: genetic factors, accelerated platelet turnover, up-regulation of the P2Y12 pathways, high baseline platelet reactivity, poor compliance, under-dosing and drug-drug interactions. The management of these patients is very difficult, but some evidence showed that a strategy of higher maintenance dose or switch to different thienopyridine (e.g. ticlopidine or prasugrel) or use of glycoprotein IIb/IIIa inhibitors during PCI may be helpful to overcome poor responsiveness and improve the long-term clinical outcome. This paper reviews the impact of clopidogrel poor responsiveness on clinical outcomes, the mechanisms leading to poor effect and the different assays to assess it. Finally, current and future options for its management is discussed.

This is a preview of subscription content, log in to check access.


  1. 1.

    Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102:624–629

  2. 2.

    Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg G, Slama M, Milleron O, Collet JP, Henry Beygui F, Drouet L (2006) A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes. The ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial. J Am Coll Cardiol 48:931–938

  3. 3.

    Patti G, Colonna G, Pasceri V et al (2005) Randomized trial of high loading dose of clopidogrel for reduction of periprocedurale myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for reduction of myocardial damage during angioplasty) study. Circulation 111:2099–2106

  4. 4.

    Cuisset T, Frere C, Quilici J et al (2006) Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48:1339–1345

  5. 5.

    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505–1516

  6. 6.

    Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, Lachno DR, Salazar D, Winters KJ (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429–2436

  7. 7.

    Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244–2247

  8. 8.

    Tabassome S, Verstuyft C, Mary-Krause M, Quteineh L, Drouet W, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L (2009) Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. N Engl J Med 360:363–375

  9. 9.

    Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gussem P (2003) Adenosine diphosphate induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989–995

  10. 10.

    Von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schoming A, Kastrati A (2005) P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 16:199–204

  11. 11.

    Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS (2007) Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 119:355–360

  12. 12.

    Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS et al (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107:32–37

  13. 13.

    Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D (2003) Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108:921–924

  14. 14.

    Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K (2007) Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 50:291–295

  15. 15.

    Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J (2006) Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin (letter). J Thromb Haemost 4:2508–2509

  16. 16.

    Gilard M, Arnaud B, Cornily JC (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256–260

  17. 17.

    Cuisset T, Frere C, Quilici J (2009) Comparison of omeprazole and pantoprazole influence on high 150-mg clopidogrel maintenance dose. The PACA (proton pump inhibitors and clopidogrel association) prospective randomized trial. J Am Coll Cardiol 54:1149–1153

  18. 18.

    Ho PM, Maddox TM, Wang L (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301:937–944

  19. 19.

    Juurlink D, Gomes T, Ko D (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180:713–718

  20. 20.

    O’Donoghue ML, Braunwald E, Antman EM (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374:989–997

  21. 21.

    Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US (2005) Clopidogrel effect on platelet REactivity in patients with stent thrombosis results of the CREST study. J Am Coll Cardiol 46:1827–1832

  22. 22.

    Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Büttner HJ, Neumann FJ (2006) Impact of the Degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48:1742–1750

  23. 23.

    Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US (2005) Platelet reactivity in patients and recurrent events post-stenting results of the prepare post-stenting study. J Am Coll Cardiol 46:1820–1826

  24. 24.

    Buonamici P, Marcucci R, Migliorini A, Genuini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D (2006) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosisD. J Am Coll Cardiol 48:2318–2319

  25. 25.

    Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Figlioli C, Buonamici P, Antoniucci D, Abbate R, Genuini GF (2009) Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay A 12-month follow-up. Circulation 119:237–242

  26. 26.

    Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A, Di Sciascio G (2008) Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol 52:1128–1133

  27. 27.

    Barragan P, Bouvier JL, Roquebert PO (2003) Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59:295–302

  28. 28.

    Blindt B, Stellbrink K, de Taeye A, Muller R, Jiefer P, Yagmur E, Weber C, Kelm M, Hoffmann R (2007) The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 98:1329–1334

  29. 29.

    Sibbing D, Braun S, Morath T (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53:849–856

  30. 30.

    Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease. Results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 115:708–716

  31. 31.

    Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ (2009) Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 157:818–824

  32. 32.

    Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F (2008) Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance a multicenter randomized prospective study. J Am Coll Cardiol 51:1404–1411

  33. 33.

    Aleil B, Rochouxs G, Monassier JP, Cazenave JP, Gachet C (2006) Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogre: a report of three cases. J Thromb Haemost 5:879–881

  34. 34.

    Campo G, Valgimigli M, Gemmati D, Percoco G, Catozzi L, Frangione A, Federici F, Ferrari F, Tebaldi M, Luccarelli S, Parrinello G, Ferrari R (2007) Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 50:1132–1137

  35. 35.

    Cuisset T, Frere C, Quilici J, Morange PE, Mouret JP, Bali L, Moro PJ, Lambert M, Alessi MC, Bonnet JL (2008) Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 1:649–653

  36. 36.

    Valgimigli M, Campo G, De Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R (2009) Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation 119:3215–3222

  37. 37.

    Wiviott SD, Trenk D, Frelinger AL, O’Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation—thrombolysis in myocardial infarction 44 trial. Circulation 116:2923–2932

  38. 38.

    Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM (2009) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 357:2001–2015

  39. 39.

    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057

Download references


The authors thank Dr. Monia Monti, Dr Stefania Gambetti and Dr Laura Bristot (Medical Trials Analysis, Italy) for their assistance in collecting data.

Author information

Correspondence to Gianluca Campo.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Campo, G., Fileti, L., Valgimigli, M. et al. Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis 30, 319–331 (2010).

Download citation


  • Clopidogrel
  • Resistance
  • VerifyNow
  • Multiplate analyzer
  • Prasugrel